Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 8Gastrointestinal 4Thoracic 3Gynecologic 3Breast 3Genitourinary 2CNS 1

Conditions

Ovarian Neoplasms 23Peritoneal Neoplasms 18Colorectal Neoplasms 10Stomach Neoplasms 9Fallopian Tube Neoplasms 8Endometrial Neoplasms 8Colonic Neoplasms 7Neoplasm Metastasis 6Carcinoma, Ovarian Epithelial 6Rectal Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 4Pancreatic Neoplasms 4Carcinoma, Renal Cell 4Appendiceal Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Neoplasms 3Esophageal Neoplasms 3Carcinoma, Hepatocellular 3Uterine Neoplasms 2Urinary Bladder Neoplasms 2Pseudomyxoma Peritonei 2Prostatic Neoplasms 2Neuroblastoma 2Melanoma 2Lung Neoplasms 2Gallbladder Neoplasms 2Cholangiocarcinoma 2Breast Neoplasms 2

Interventions

pembrolizumab 35Paclitaxel 10Nivolumab 10Carboplatin 9atezolizumab 7Docetaxel 7Cisplatin 7Ipilimumab 5Gemcitabine 5Cyclophosphamide 5spartalizumab 4fludarabine 4Fluorouracil 4lenvatinib 3durvalumab 3cemiplimab 3avelumab 3Vorinostat 3Trastuzumab 3Oxaliplatin 3Leucovorin 3Immunoglobulin G 3Fulvestrant 3Cetuximab 3Bevacizumab 3zimberelimab 2tisotumab vedotin 2tislelizumab 2sargramostim 2aldesleukin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Squamous Cell Carcinoma of Head and Neck × Oxaliplatin × Gynecologic × Clear all
NCT05891171 2026-03-31

ARC-25

Arcus Biosciences, Inc.

Phase 1 Active not recruiting
40 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT05007106 2025-08-14

KEYVIBE-005

Merck Sharp & Dohme LLC

Phase 2 Completed
613 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT02658214 2020-08-20

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

AstraZeneca

Phase 1 Completed
32 enrolled
BreastGastrointestinalGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms, Stomach Neoplasms, Carcinoma, Pancreatic Ductal, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡